Free Trial
NASDAQ:CARM

Carisma Therapeutics Q2 2024 Earnings Report

Carisma Therapeutics logo
$0.22 +0.00 (+2.23%)
As of 03:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Carisma Therapeutics EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Carisma Therapeutics Revenue Results

Actual Revenue
$9.20 million
Expected Revenue
$3.65 million
Beat/Miss
Beat by +$5.55 million
YoY Revenue Growth
N/A

Carisma Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Carisma Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Carisma Therapeutics Earnings Headlines

Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Carisma Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Carisma Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your email.

About Carisma Therapeutics

Carisma Therapeutics (NASDAQ:CARM), a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

View Carisma Therapeutics Profile

More Earnings Resources from MarketBeat